GrandPharm obtained the right to commercialize BRM421,a new drug for dry eye syndrome, in mainland China, HK and Macau.

Target Company Name:
Country:
Advisory:
Sector:
Partner:

BRM421
Taiwan
Advisor to the seller
Healthcare & Pharmaceuticals

GrandPharm obtained the right to develop and commercialize BRM421 in greater China. At the same time, GrandPharm subscribed for a small amount of equity of Brimbiotech

BRM421

Grandpharma

GrandPharm obtained the right to commercialize BRM421,a new drug for dry eye syndrome, in mainland China, HK and Macau.

Advisor to the seller

Relevant transactions

Transactions

Project Amygdala

Private Equity

Sale of mental health services provider for high-acuity individuals in the UK

Advisor to the seller :
Cooper Parry Corporate Finance

Private Investors

Sale of a minority stake of Genbio, a hemoderivatives producer, to Private Investors

Advisor to the seller :
RIóN

icotec, the world leader in the field of spinal tumor implants, has closed its USD 30m growth financing round led by MVM

Advisor

Alpha Source Group, a portfolio company of Baird Capital, acquired by Probo Medical.

Advisor to the seller :
Brown Gibbons Lang & Company